Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Agreement With J&J Clears Path For Partners To Launch Ustekinumab Biosimilar
Executive Summary
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.